Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

BACKGROUND: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. METHODS: Healthy postmenopausal osteoporotic women (N = 7,492; mean ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Christiansen, Claus, Chesnut, Charles H, Adachi, Jonathan D, Brown, Jacques P, Fernandes, César E, Kung, Annie WC, Palacios, Santiago, Levine, Amy B, Chines, Arkadi A, Constantine, Ginger D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908075/
https://www.ncbi.nlm.nih.gov/pubmed/20569451
http://dx.doi.org/10.1186/1471-2474-11-130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908075/
https://www.ncbi.nlm.nih.gov/pubmed/20569451
http://dx.doi.org/10.1186/1471-2474-11-130

Ejemplares similares